Its tumor-specific expression and association with aggressive clinical features nominate DOCK3 as a novel biomarker for risk stratification and a promising therapeutic target for combinatorial immunotherapy in immunologically “cold” PCa. Here, DOCK3 is linked to posterior cortical atrophy.